Bodhaya

Bodhaya is a biotechnology company dedicated to developing the next generation of medicines for brain health, with a primary focus on neuropsychiatric and neurological disorders. The company leverages a proprietary drug discovery platform to design and develop psychoplastogens—small molecules capable of promoting neural plasticity. Bodhaya's lead programs focus on creating non-hallucinogenic analogs of psychedelic compounds, aiming to provide the therapeutic benefits of psychedelics without the associated hallucinogenic effects or the need for intensive clinical supervision. By targeting specific serotonin receptors, the company seeks to address high unmet needs in conditions such as treatment-resistant depression, anxiety, and PTSD. Bodhaya is currently in the pre-clinical stage of development for its lead candidates.